Form 4 for CUE Cue Biopharma, Inc.
Accepted 2022-05-25 00:00:00 ET · period of report 2022-05-23 · accession 0001209191-22-031791 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2022-05-25 | 2022-05-23+ | CUE | Fletcher Aaron G.L. | Dir | P - Purchase | $3.47 | +205.0K | 940.0K | +28% | +$711.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-23 | P | A | 150,000 | $3.52 | 885,000 | I See footnote | — | — | (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.31 to $3.62. The price reported in Column 4 is a weighted average price. (F2) The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. |
| 2 | Common | Common Stock | 2022-05-24 | P | A | 55,000 | $3.34 | 940,000 | I See footnote | — | — | (F3) The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.21 to $3.52. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Cue Biopharma, Inc., any stockholder of Cue Biopharma, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3). (F2) The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. |